← Leaderboards
Philip Breitfeld
Fannin Partners, Llc
$1,042,155
Attributed
$2,084,309
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1000K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,084,309 · 1
By mechanism
R44$2,084,309 · 1
Top collaborators
- Atul Varadhachary3 shared
Others in their field
Other Rising Stars on “Drug Kinetics”
- Kevin V Grimes · Stanford University$14,783,804
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
- Alexander Kolykhalov · Emory University$8,116,465
Research focus
Drug KineticsIl7 GeneCancer PreventionDoseFundingIgg1Cancer GeneticsAntibody-Dependent Cell CytotoxicityAnticancer ActivityClinical TrialsFda ApprovedFirst-In-HumanApplications GrantsGrantAntibodiesAdultB-Cell Acute Lymphoblastic LeukemiaBindingBiologicalBiological MarkersChildClinical DevelopmentAcute T Cell LeukemiaIl7r Gene
Grant awards (3)
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$999,997
R44 · FY2025 · CA
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$84,315
R44 · FY2023 · CA
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$999,997
R44 · FY2022 · CA